On May 14th Avivagen announced the appointment of two new board of directors; David Allan and Vanessa Grant. Two previous directors have resigned, Dr. Janusz Daroszewski and Dr. Chandra Panchal. The appointments of Allan and Grant remain subject to TSX Venture Exchange approvals.
Allan was the Chairman and CEO of YM BioSciences Inc. from 1998 to 2010. He was the founding Chairman of AvidBiologics, the Executive Chairman of Stem Cell Therapeutics Corp., and the Lead Director of DiaMedica Inc. Allan has also been a CEO or senior executive of three Canadian investment dealers and a Governor of the Toronto Stock Exchange. Regarding his appointment, Allen said, “I’ve long been interested in Avivagen’s important positioning, have a meaningful shareholding and am pleased to be appointed to its Board of Directors. I believe Avivagen’s OxC-beta technology provides multiple business prospects that I may help it realize.”
Grant is experienced in corporate governance, capital markets, life sciences, and agriculture. She is a business law partner in Gowling Lafleur Henderson LLP. Grant has advised life sciences companies and is the Co-Director of York University’s Osgoode Hall Law School; she teaches corporate finance. Grant is “Very pleased to be appointed to Avivagen’s Board of Directors and look forward to using my skills to help ensure the success of the Company. I believe Avivagen has exciting opportunities with its products and intend to work hard to assist with realizing that potential.”
